HRTIS Herantis Pharma Oyj

1.344EUR-4.00%Mkt Cap: 38.72M $P/E: 67.20

Herantis Pharma Oyj, a clinical stage biotechnology company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson's disease (PD). The company's lead p…

Key Statistics

Company
Market Cap38.72M USD
Enterprise Value36.54M USD
Revenue (TTM)-146.74K USD
Gross Profit-146.74K USD
Net Income (TTM)-7.20M USD
Revenue/Share-0.0050 EUR
Last Price1.344 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees14
CountryFI
SectorHealthcare
IndustryBiotechnology
ISINFI4000087861
Valuation
P/E (Trailing)67.20
P/E (Forward)-7.78
PEG—
EV/EBITDA—
EV/Revenue-249.04
P/S-274.85
P/B-46.67
EPS (TTM)0.02
EPS (Forward)-0.18
52W Range
1.3201% of range3.870
52W High3.870 EUR
52W Low1.320 EUR
Profitability
Gross Margin0.00%
Oper. Margin4817.53%
EBITDA Margin0.00%
Profit Margin0.00%
ROE392.28%
ROA-248.09%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-6.63M USD
CapEx (TTM)—
FCF Margin2429.48%
FCF Yield-9.21%
Net Debt-3.79M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity-0.01
Current Ratio2.89
Quick Ratio2.60
Book Value/Sh-0.03 EUR
Cash/Share0.13 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 EUR
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)2.000 EUR
Upside (mean)+48.8%
Target Range2.000 EUR – 2.000 EUR
# Analysts1
Ownership
Shares Out.26.50M
Float16.79M
Insiders23.76%
Institutions22.69%
Technical
SMA 501.541 (-12.8%)
SMA 2001.842 (-27.0%)
Beta0.63
S&P 52W Chg16.45%
Avg Vol (30d)23.93K
Avg Vol (10d)20.39K
Technical Indicators
RSI (14)35.8
MACD-0.0464
MACD Signal-0.0502
MACD Hist.+0.0038
BB Upper1.466 EUR
BB Middle1.407 EUR
BB Lower1.348 EUR
BB Width8.43%
ATR (14)0.0657 EUR
Vol Ratio (20d)0.43x